<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937751</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI202</org_study_id>
    <nct_id>NCT04937751</nct_id>
  </id_info>
  <brief_title>Markers of Infection and Resistance in Invasive Fusariosis</brief_title>
  <acronym>FUSIMIR</acronym>
  <official_title>Multicenter Study on Invasive Fusariosis : Looking for Markers of Infection and Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent decades, invasive fusarioses have been emerging fungal pathologies with high&#xD;
      mortality. The prognosis depends on the speed of the diagnosis, but currently biological&#xD;
      diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is&#xD;
      available in current clinical practice. The genus Fusarium also shows reduced sensitivity to&#xD;
      antifungals commonly used and recommended in clinical practice, such as voriconazole or&#xD;
      amphotericin B.&#xD;
&#xD;
      The main objective of this study is to describe the proportions of different fungal species&#xD;
      in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal&#xD;
      keratitis. The secondary objectives are the description of the dosage of galactomannans, beta&#xD;
      (1,3) -D-glucans and the rate of detection of DNA circulating in case / control groups for&#xD;
      the 2 clinical forms studied. In patients with evidence of Fusarium wilt, the study will&#xD;
      describe the distribution of the different minimum inhibitory concentrations (MIC) depending&#xD;
      on whether or not different antifungals are taken, the vital status at 3 months, and the&#xD;
      response or not to treatment. Finally, the presence of genetic markers will be described&#xD;
      according to the groups of MIC values.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis</measure>
    <time_frame>2021-2026</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fusariosis</condition>
  <arm_group>
    <arm_group_label>Invasive fusariosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fusarium keratitis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>biomarkers</intervention_name>
    <description>galactomannan, betaDglucan, resistance markers</description>
    <arm_group_label>Fusarium keratitis</arm_group_label>
    <arm_group_label>Invasive fusariosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and fungal strains&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will have 2 parts:&#xD;
&#xD;
          1. a first descriptive section carried out through a study of 2 cohorts of patients&#xD;
             (patients suspected of IFI / with a diagnosis of keratitis) for whom a fungal culture&#xD;
             is carried out;&#xD;
&#xD;
          2. a second descriptive part (then potentially comparative if the statistical power is&#xD;
             sufficient) carried out through 2 case-control studies nested in each of the patient&#xD;
             cohorts (patients suspected of IFI / with a diagnosis of keratitis): these studies&#xD;
             will consist of a population of cases (patients with Fusarium wilt) and 1 or 2&#xD;
             populations of controls (patients with negative culture on the one hand and patients&#xD;
             with positive culture for a fungus of another genus in Fusarium on the other hand for&#xD;
             invasive fusarioses).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspicion of invasive fungal infection involving the performance of a blood culture or&#xD;
             a skin biopsy or diagnosis of keratitis involving the taking of a cornea sample&#xD;
&#xD;
          -  Fungal culture carried out on this sample&#xD;
&#xD;
          -  Person having been informed of the research and not having opposed the use of their&#xD;
             data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of superficial fusarium wilt (onychomycosis, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Anne DEBOURGOGNE</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fusariosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

